FDA Approval Summary: Olaparib Monotherapy in Patients with Deleterious Germline <i>BRCA</i>-Mutated Advanced Ovarian Cancer Treated with Three or More Lines of Chemotherapy
Geoffrey Kim(United States Food and Drug Administration), Richard Pazdur(United States Food and Drug Administration), Haw-Jyh Chiu(United States Food and Drug Administration), Reena Philip(Center for Devices and Radiological Health), Anne‐Marie Russell(Birmingham City University), Shenghui Tang(United States Food and Drug Administration), Rajesh Venugopal(United States Food and Drug Administration), Todd R. Palmby(University of North Carolina at Chapel Hill), Abraham Tzou(Center for Devices and Radiological Health), Elimika Pfuma(United States Food and Drug Administration), Gwynn Ison(United States Food and Drug Administration), Thomas Gwise(United States Food and Drug Administration), Tiffany K. Ricks(United States Food and Drug Administration), Hui Zhang(Shanghai Medical College of Fudan University), Qi Liu(United States Food and Drug Administration), Eunice Lee(Center for Devices and Radiological Health), Hongshan Li(United States Food and Drug Administration), Amy E. McKee(United States Food and Drug Administration), Gaétan Ladouceur(Center for Drug Evaluation and Research), Liang Zhao(United States Food and Drug Administration), Rajeshwari Sridhara(Center for Drug Evaluation and Research), Amna Ibrahim(United States Food and Drug Administration)
Cited by 526
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
FDA Approval Summary: Vorinostat for Treatment of Advanced Primary Cutaneous T-Cell Lymphoma
|The Oncologist|2007|1.4k
FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors
|Clinical Cancer Research|2019|1.2k